Can you switch from Levemir to Lantus one-for-one?
Often you cannot use a strict 1:1 switch. Levemir (detemir) and Lantus (glargine) have different dosing patterns and durations of action, so the total daily basal dose may need adjustment when you change products. Your prescriber will usually base the starting Lantus dose on your current Levemir dose and how often you take Levemir (once vs twice daily), then fine-tune using glucose readings.
What’s the usual step-by-step way clinicians transition basal insulin?
A safe switch generally includes:
- Start Lantus at the next scheduled basal insulin time rather than stopping and “waiting.”
- Use a conversion calculated from your current Levemir regimen (including whether you take it once or twice daily).
- Monitor blood glucose more closely during the first days because basal insulins can overlap differently and may change your risk of lows or highs.
- Adjust only with guidance from your clinician (or per a pre-written plan) based on several days of readings.
If you take Levemir once daily, how is Lantus typically started?
When Levemir is taken once daily, the prescriber may start Lantus once daily using a basal-dose conversion and then adjust based on fasting and overnight glucose. Because different insulin profiles can shift overnight glucose, the first adjustment decisions often rely on morning fasting numbers and bedtime/overnight checks (if you do those).
If you take Levemir twice daily, how does that change the switch?
For people on Levemir twice daily, the clinician may calculate the total daily Levemir dose (morning + evening) and then choose a starting Lantus dose that fits once-daily basal coverage. Since Lantus is typically given once daily, the dose may be similar but often needs adjustment to maintain overnight and early-morning control.
How much should you test after switching to avoid hypoglycemia or hyperglycemia?
More frequent glucose checks for the first several days are key to safety, especially around:
- Overnight (if you’re prone to nighttime lows)
- Fasting (to see if the basal dose is enough overnight)
- Late day and bedtime (to catch under-dosing before the next dose)
If you use continuous glucose monitoring, your clinician may suggest targeting time-in-range and watching for drifting lows or highs during the transition window.
What are the biggest safety risks during the switch?
The main risks are:
- Hypoglycemia (especially if the new basal dose overlaps more than expected or if your timing differs)
- Hyperglycemia (if the new dose is too low to cover overnight needs)
- “Stacking” mistakes (taking both insulins too close together or not spacing doses correctly)
Following the exact timing plan is often as important as the dose number.
What should you do if your sugars run high or low right after the switch?
If your glucose is running low, you generally do not “wait it out” without a plan. Contact your prescriber for dose guidance. If readings run high, your prescriber may adjust the basal dose after a short period of data. Safety-focused transitions usually use a pre-agreed adjustment rule rather than ad-hoc changes.
Any special considerations for timing, kidney disease, or changing schedules?
Yes. Basal insulin needs can change with:
- Reduced kidney function (higher hypoglycemia risk)
- Changes in diet, activity, or work/sleep schedule (especially around overnight)
- Pregnancy or recent changes in body weight
If any of these apply, you should ask your clinician for a tighter monitoring plan during the switch.
Can you switch without medical supervision?
No—insulin dose conversion and monitoring require individualized adjustment. Even though the switch can be done in days, it can be unsafe to do without guidance because your current Levemir regimen (once vs twice daily), your typical glucose patterns, and your hypoglycemia risk all affect the starting Lantus dose.
If you tell me:
1) your current Levemir dose and whether it’s once or twice daily,
2) your typical fasting and bedtime glucose,
3) any history of nighttime lows,
I can help you translate that into the questions to ask your prescriber and what monitoring targets to watch during the transition.